Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Journal of Gynecologic Oncology ; : e51-2016.
Artículo en Inglés | WPRIM | ID: wpr-216444

RESUMEN

Cervical cancer is the fourth most lethal women's cancer worldwide. Current treatments against cervical cancer include surgery, radiotherapy, chemotherapy, and anti-angiogenic agents. However, despite the various treatments utilized for the treatment of cervical cancer, its disease burden remains a global issue. Persistent infection of human papillomavirus (HPV) has been identified as an essential step of pathogenesis of cervical cancer and many other cancers, and nation-wide HPV screening as well as preventative HPV vaccination program have been introduced globally. However, even though the commercially available prophylactic HPV vaccines, Gardasil (Merck) and Cervarix (GlaxoSmithKline), are effective in blocking the entry of HPV into the epithelium of cervix through generation of HPV-specific neutralizing antibodies, they cannot eliminate the pre-existing HPV infection. For these reason, other immunotherapeutic options against HPV-associated diseases, including therapeutic vaccines, have been continuously explored. Therapeutic HPV vaccines enhance cell-mediated immunity targeting HPV E6 and E7 antigens by modulating primarily dendritic cells and cytotoxic T lymphocyte. Our review will cover various therapeutic vaccines in development for the treatment of HPV-associated lesions and cancers. Furthermore, we will discuss the potential of immune checkpoint inhibitors that have recently been adopted and tested for their treatment efficacy against HPV-induced cervical cancer.


Asunto(s)
Femenino , Humanos , Células Dendríticas/inmunología , Vectores Genéticos , Inmunoterapia , Infecciones por Papillomavirus/complicaciones , Vacunas contra Papillomavirus/uso terapéutico , Investigación Biomédica Traslacional , Neoplasias del Cuello Uterino/terapia , Vacunas de ADN/uso terapéutico , Vacunas de Subunidad/uso terapéutico
2.
Indian J Hum Genet ; 2011 May; 17(Suppl 1): 22-26
Artículo en Inglés | IMSEAR | ID: sea-138980

RESUMEN

Pharmacogenomics and pharmacogenetics are promising in development of a personalized treatment approach They are of paramount importance for basic immunology, for peptide based vaccine design (vaccinomics) drug monitoring in clinical setting and molecular pathophysiology of multifactorial diseases like cancer, tuberculosis, cardiac disorders, diabetes, asthma, HIV, etc


Asunto(s)
Síndrome de Inmunodeficiencia Adquirida/tratamiento farmacológico , Síndrome de Inmunodeficiencia Adquirida/terapia , VIH/efectos de los fármacos , VIH/genética , VIH/inmunología , Humanos , Farmacogenética/métodos , Vacunas de Subunidad/inmunología , Vacunas de Subunidad/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA